Experimental cell therapy offers hope for lymphoma patients out of options
NCT ID NCT05618925
Summary
This early-stage study is testing the safety of a new cell therapy called CD19 t-haNK for adults with non-Hodgkin lymphoma that has returned or hasn't responded to previous treatments. The study will enroll 20 participants to test the therapy alone and in combination with two other drugs. The main goal is to understand side effects and see if this approach shows any promise against the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN'S LYMPHOMA REFRACTORY/RELAPSED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hoag Memorial Hospital
RECRUITINGNewport Beach, California, 92663, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Texas Oncology
RECRUITINGTyler, Texas, 75702, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.